PMID- 23964810
OWN - NLM
STAT- MEDLINE
DCOM- 20141117
LR  - 20220129
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 16
IP  - 3
DP  - 2014 Mar
TI  - The effect of antiobesity drugs on waist circumference: a mixed treatment 
      comparison.
PG  - 237-47
LID - 10.1111/dom.12198 [doi]
AB  - AIM: To use meta-analytic techniques to quantitatively evaluate the efficacy of 
      orlistat and lorcaserin in the treatment of people who are overweight and obese. 
      METHODS: We identified publications from searches of electronic databases and 
      extracted data from studies that compared orlistat or lorcaserin to lifestyle 
      advice (standard care), placebo, sibutramine, rimonabant or metformin and 
      collected information on waist circumference change or withdrawals due to adverse 
      events (AEs). A mixed treatment comparison (MTC) meta-analysis was performed on 
      the data extracted. RESULTS: Orlistat was found to be significantly better than 
      placebo and standard care in reducing waist circumference at 6 and 12 months; 
      orlistat reduced waist circumference by -6.96 cm [95% credible interval (CrI): 
      -8.93, -4.96 cm] compared to standard care at 6 months. The results suggested 
      that lorcaserin reduced waist circumference by a greater amount than all other 
      interventions at 12 months, for example, lorcaserin lead to a greater reduction 
      of -2.45 cm (95% CrI: -4.99, 0.08 cm) in comparison to placebo, although these 
      differences were not statistically significant. Although data were very limited, 
      metformin reduced waist circumference by a greater amount (-2.11 cm, 95% CI: 
      -1.00, -3.22 cm) than orlistat at 6 months. On average, 6.5% of patients on 
      orlistat and 5.4% of those on lorcaserin discontinued their treatment due to AEs 
      at 12 months. CONCLUSIONS: Orlistat should be considered as an addition to 
      lifestyle interventions in the treatment of obesity. Lorcaserin has recently been 
      approved by the US Food and Drug Administration (FDA) and these results suggest 
      that it is similar in both efficacy and safety compared to orlistat.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Chilton, M
AU  - Chilton M
AD  - Department of Health Sciences, University of Leicester, Leicester, UK.
FAU - Dunkley, A
AU  - Dunkley A
FAU - Carter, P
AU  - Carter P
FAU - Davies, M J
AU  - Davies MJ
FAU - Khunti, K
AU  - Khunti K
FAU - Gray, L J
AU  - Gray LJ
LA  - eng
GR  - RP-DG-1210-10183/DH_/Department of Health/United Kingdom
GR  - RP-PG-0606-1272/DH_/Department of Health/United Kingdom
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130915
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Anti-Obesity Agents)
RN  - 0 (Benzazepines)
RN  - 0 (Lactones)
RN  - 637E494O0Z (lorcaserin)
RN  - 9100L32L2N (Metformin)
RN  - 95M8R751W8 (Orlistat)
SB  - IM
MH  - Anti-Obesity Agents/*administration & dosage/adverse effects
MH  - Benzazepines/*administration & dosage/adverse effects
MH  - Body Mass Index
MH  - Combined Modality Therapy
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Lactones/*administration & dosage/adverse effects
MH  - Male
MH  - Metformin/*administration & dosage/adverse effects
MH  - Obesity/*drug therapy
MH  - Orlistat
MH  - Risk Reduction Behavior
MH  - Treatment Outcome
MH  - Waist Circumference/*drug effects
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - lorcaserin
OT  - meta-analysis
OT  - obesity
OT  - orlistat
EDAT- 2013/08/24 06:00
MHDA- 2014/11/18 06:00
CRDT- 2013/08/23 06:00
PHST- 2013/05/12 00:00 [received]
PHST- 2013/06/20 00:00 [revised]
PHST- 2013/08/14 00:00 [accepted]
PHST- 2013/08/23 06:00 [entrez]
PHST- 2013/08/24 06:00 [pubmed]
PHST- 2014/11/18 06:00 [medline]
AID - 10.1111/dom.12198 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2014 Mar;16(3):237-47. doi: 10.1111/dom.12198. Epub 2013 Sep 
      15.